J Wu1,2, W Li3, X Shi1, Z Chen2, B Jiang4, J Liu5, D Wang6, C Liu7, Y Meng8, L Cui2, J Yu1, H Cao1,9, L Li1. 1. From the, State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. 2. Department of Laboratory Medicine, The First People's Hospital of Yancheng City, Yancheng, China. 3. Department of Hepatology, The Second People's Hospital of Fuyang City, Fuyang, China. 4. Department of Laboratory Medicine, The Central Blood Station of Yancheng City, Jiangsu, China. 5. Department of Laboratory Medicine, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University, Wuxi, China. 6. Department of Infectious Disease, The Second People's Hospital of Yancheng City, Yancheng, China. 7. Department of Infectious Disease, The First People's Hospital of Yancheng City, Yancheng, China. 8. Department of Laboratory Medicine, Suzhou Vocational Health College, Suzhou, China. 9. Zhejiang Provincial Key Laboratory for Diagnosis and Treatment of Aging and Physic-chemical Injury Diseases, Hangzhou, China.
Abstract
BACKGROUND: At present, the severity of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focal point. METHODS: To assess the factors associated with severity and prognosis of patients infected with SARS-CoV-2, we retrospectively investigated the clinical, imaging and laboratory characteristics of confirmed 280 cases of novel coronavirus disease (COVID-19) from 20 January to 20 February 2020. RESULTS: The median age of patients in the mild group was 37.55 years, whilst that in the severe group was 63.04 years. The proportion of patients aged over 65 years in the severe group was significantly higher than that of the mild group (59.04% vs. 10.15%, P < 0.05). 85.54% of severe patients had diabetes or cardiovascular diseases, which was significantly higher than that of the mild group (51.81% vs. 7.11%, P = 0.025; 33.73% vs. 3.05%, P = 0.042). Patients in the mild group experienced earlier initiation of antiviral treatment (1.19 ± 0.45 vs. 2.65 ± 1.06 days in the severe group, P < 0.001). Our study showed that comorbidity, time from illness onset to antiviral treatment and age >=65 were three major risk factors for COVID-19 progression, whilst comorbidity and time from illness onset to antiviral treatment were two major risk factors for COVID-19 recovery. CONCLUSIONS: The elderly and patients with underlying diseases are more likely to experience a severe progression of COVID-19. It is recommended that timely antiviral treatment should be initiated to slow the disease progression and improve the prognosis.
BACKGROUND: At present, the severity of patientsinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focal point. METHODS: To assess the factors associated with severity and prognosis of patientsinfected with SARS-CoV-2, we retrospectively investigated the clinical, imaging and laboratory characteristics of confirmed 280 cases of novel coronavirus disease (COVID-19) from 20 January to 20 February 2020. RESULTS: The median age of patients in the mild group was 37.55 years, whilst that in the severe group was 63.04 years. The proportion of patients aged over 65 years in the severe group was significantly higher than that of the mild group (59.04% vs. 10.15%, P < 0.05). 85.54% of severe patients had diabetes or cardiovascular diseases, which was significantly higher than that of the mild group (51.81% vs. 7.11%, P = 0.025; 33.73% vs. 3.05%, P = 0.042). Patients in the mild group experienced earlier initiation of antiviral treatment (1.19 ± 0.45 vs. 2.65 ± 1.06 days in the severe group, P < 0.001). Our study showed that comorbidity, time from illness onset to antiviral treatment and age >=65 were three major risk factors for COVID-19 progression, whilst comorbidity and time from illness onset to antiviral treatment were two major risk factors for COVID-19 recovery. CONCLUSIONS: The elderly and patients with underlying diseases are more likely to experience a severe progression of COVID-19. It is recommended that timely antiviral treatment should be initiated to slow the disease progression and improve the prognosis.
Authors: Nicholas Hartog; William Faber; Austin Frisch; Jacob Bauss; Caleb P Bupp; Surender Rajasekaran; Jeremy W Prokop Journal: Expert Rev Proteomics Date: 2021-04-05 Impact factor: 3.940
Authors: Pablo Abuin; Alejandro Anderson; Antonio Ferramosca; Esteban A Hernandez-Vargas; Alejandro H Gonzalez Journal: Annu Rev Control Date: 2021-05-28 Impact factor: 6.091
Authors: Christine J Kubin; Thomas H McConville; Donald Dietz; Jason Zucker; Michael May; Brian Nelson; Elizabeth Istorico; Logan Bartram; Jennifer Small-Saunders; Magdalena E Sobieszczyk; Angela Gomez-Simmonds; Anne-Catrin Uhlemann Journal: Open Forum Infect Dis Date: 2021-05-05 Impact factor: 3.835